Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials

References

• Miettinen M Lasota J Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis Arch Pathol Lab Med 2008 130 1466 1478 17090188
   PubMed Web of Science ®Google Scholar
• Corless CL Barnett CM Heinrich MC Gastrointestinal stromal tumours: origin and molecular oncology Nat Rev Cancer 2011 11 865 878 22089421
   PubMed Web of Science ®Google Scholar
• Mullady DK Tan BR A multidisciplinary approach to the diagnosis and treatment of gastrointestinal stromal tumor J Clin Gastroenterol 2013 47 578 585 23751846
   PubMed Web of Science ®Google Scholar
• Angelini S Ravegnini G Fletcher JA Maffei F Hrelia P Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy Pharmacogenomics 2013 14 941 956 23746188
   PubMed Web of Science ®Google Scholar
• Heinrich MC Corless CL Demetri GD Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 2003 21 4342 4349 14645423
   PubMed Web of Science ®Google Scholar
• Judson I Leahy M Whelan J A guideline for the management of gastrointestinal stromal tumour (GIST) Sarcoma 2002 6 83 87 18521337
   PubMedGoogle Scholar
• Antonescu CR The GIST paradigm: lessons for other kinase-driven cancers J Pathol 2011 223 251 261 21125679
   PubMed Web of Science ®Google Scholar
• Demetri GD von Mehren M Blanke CD Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 2002 347 472 480 12181401
   PubMed Web of Science ®Google Scholar
• Antonescu CR Besmer P Guo T Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation Clin Cancer Res 2005 11 4182 4190 15930355
   PubMed Web of Science ®Google Scholar
• Gounder MM Maki RG Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor Cancer Chemother Pharmacol 2011 67 S25 S43 21116624
   PubMed Web of Science ®Google Scholar
• Demetri GD van Oosterom AT Garrett CR Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial Lancet 2006 368 1329 1338 17046465
   PubMed Web of Science ®Google Scholar
• Demetri GD Garrett CR Schöffski P Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure Clin Cancer Res 2012 18 3170 3179 22661587
   PubMed Web of Science ®Google Scholar
• Abrams TJ Lee LB Murray LJ Pryer NK Cherrington JM SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer Mol Cancer Ther 2003 2 471 478 12748309
   PubMed Web of Science ®Google Scholar
• Mendel DB Laird AD Xin X In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 2003 9 327 337 12538485
   PubMed Web of Science ®Google Scholar
• Le Cesne A Blay JY Bui BN Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST) Eur J Cancer 2010 46 1344 1351 20211560
   PubMed Web of Science ®Google Scholar
• Benjamin RS Schöffski P Hartmann JT Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors Cancer Chemother Pharmacol 2011 68 69 77 20838998
   PubMed Web of Science ®Google Scholar
• Park SH Ryu MH Ryoo BY Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group Invest New Drugs 2012 30 2377 2383 22270258
   PubMed Web of Science ®Google Scholar
• Joensuu H De Braud F Grignagni G Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study Br J Cancer 2011 104 1686 1690 21540861
   PubMed Web of Science ®Google Scholar
• Demetri GD Reichardt P Kang YK Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicenter, randomized, placebo-controlled, phase 3 trial Lancet 2013 381 295 302 23177515
   PubMed Web of Science ®Google Scholar
• Reichardt P Blay JY Gelderblom H Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib Ann Oncol 2012 23 1680 1687 22357255
   PubMed Web of Science ®Google Scholar
• Blay JY von Mehren M Nilotinib: a novel, selective tyrosine kinase inhibitor Semin Oncol 2011 38 S3 S9 21419934
   PubMed Web of Science ®Google Scholar
• Manley PW Drueckes P Fendrich G Extended kinase profile and properties of the protein kinase inhibitor nilotinib Biochim Biophys Acta 2010 1804 445 453 19922818
   PubMed Web of Science ®Google Scholar
• Wilhelm SM Dumas J Adnane L Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity Int J Cancer 2011 129 245 255 21170960
   PubMed Web of Science ®Google Scholar
• Jadad AR Moore RA Carroll D Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996 17 1 12 8721797
   PubMedGoogle Scholar
• The Cochrane Collaboration Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Available from: http://handbook.cochrane.org/ Accessed May 31, 2014
   Google Scholar
• Begg CB Mazumdar M Operating characteristics of a rank correlation test for publication bias Biometrics 1994 50 1088 1101 7786990
   PubMed Web of Science ®Google Scholar
• Wang WL Conley A Reynoso D Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor Cancer Chemother Pharmacol 2011 67 S15 S24 21181476
   PubMed Web of Science ®Google Scholar
• Nannini M Biasco G Astolfi A Pantaleo MA An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST) J Med Genet 2013 50 653 661 23833252
   PubMed Web of Science ®Google Scholar